13,580.00
+2.11%
Close of 9 Nov 2026, in ILA
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Teva Pharmaceutical Industries
Its shares trade on Tel Aviv under the ticker TEVA.TA. It has been listed since 1 January 1951. In the fiscal year to 31 December 2025, it reported revenue of $18.68bn and net income of $1.53bn. At that date it held total assets of $40.76bn and shareholders' equity of $7.91bn.
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Jan 1951
- Employees
- 39,717
- Website
- tevapharm.com ↗
Leadership
Pay as last reported
- Dr. Sol BarerIndependent Chairman of the Board$539,993
- Mr. Richard FrancisPresident, Chief Executive Officer, Director, since 2023$25.7m
- Mr. Eliyahu KalifChief Financial Officer, Executive Vice President$4.9m
- Mr. Richard DaniellExecutive Vice President - European Commercial$5.2m
- Ms. Christine FoxExecutive Vice President - U.S. Commercial
- Dr. Angus GrantExecutive Vice President - Business Development
- Mr. Eric HughesExecutive Vice President - Global R & D, Chief Medical Officer
- Mr. David McAvoyExecutive Vice President, Chief Legal Officer
- Mr. Mark SabagExecutive Vice President - International Markets Commercial$3.7m
- Mr. Matthew ShieldsExecutive Vice President - Global Operations
- Ms. Vikki ConwayActing Head of Global Human Resources
- Ms. Rosemary CraneIndependent Director$329,999
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 78
- Environment
- 56
- Social
- 88
- Governance
- 90
- Direct emissions (scope 1)
- 242,056 t
- Energy emissions (scope 2)
- 349,378 t
- Value chain emissions (scope 3)
- 6,066,355 t
- Women in the workforce
- 47%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Teva Pharmaceutical Industries is a leading multinational pharmaceutical company with a strong global presence. It operates in over 60 countries and has a wide distribution network, allowing it to reach a large customer base worldwide.
- Teva offers a diverse range of pharmaceutical products, including both generic and branded drugs. This diversity helps in mitigating risks associated with any potential decline in specific product lines and provides a balanced revenue stream.
- Teva has a strong focus on research and development (R&D), investing significantly in the development of innovative drugs and technologies. This enables the company to introduce new and improved products, stay competitive in the market, and drive future growth.
Weaknesses
- Despite having a diversified product portfolio, Teva's revenue heavily relies on a few key products. Any decline in the sales of these products due to patent expirations or generic competition can significantly impact the company's financial performance.
- The pharmaceutical industry is subject to strict regulations and legal challenges. Teva faces the risk of lawsuits, such as patent disputes or allegations of improper marketing practices, which can lead to financial penalties and reputational damage.
Opportunities
- The increasing cost of healthcare and expiring patents of branded drugs present an opportunity for Teva to capitalize on the growing demand for generic drugs. By leveraging its expertise in generic pharmaceuticals, the company can expand its market share and profitability.
- Emerging markets, such as Asia and Latin America, offer significant growth potential for pharmaceutical companies. Teva can explore expansion opportunities in these markets by forming strategic partnerships, acquiring local companies, or establishing manufacturing facilities.
Threats
- The generic pharmaceutical industry is highly competitive, with numerous players vying for market share. Teva faces the risk of price erosion and margin pressure due to intense competition, potentially impacting its profitability.
- The expiration of patents on key drugs can lead to increased competition from generic manufacturers. Teva's revenue may decline if it fails to effectively replace the lost revenue with new products or face significant generic competition for its existing products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.